ArticleFrontiers in immunology2017
Deletion of TGF-β1 Increases Bacterial Clearance by Cytotoxic T Cells in a Tuberculosis Granuloma Model.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 55 citations in OpenAlex.
- Azithromycin as Host-Directed Therapy for Pulmonary Tuberculosis: A Randomized Pilot Trial.The Journal of infectious diseases · 2025Trial
- Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.Frontiers in immunology · 2021Trial
- The role of TGF-β1 C-509T and TGF-β1 T869C polymorphisms in susceptibility to tuberculosis infection in a Sudanese population: a case-control study.BMC infectious diseases · 2025Article
- Spatial transcriptomic analysis of HIV and tuberculosis coinfection in a humanized mouse model reveals unique transcription patterns, immune responses and early morphological alterations.bioRxiv : the preprint server for biology · 2025Article
- Distinguishing multiple roles of T cell and macrophage involvement in determining lymph node fates during Mycobacterium tuberculosis infection.PLoS computational biology · 2025Article
- Glucose Metabolic Reprogramming of Macrophages AgainstImmunoTargets and therapy · 2025Review
- Unveiling the immunomodulatory properties of starch microparticles on alveolar macrophages.PloS one · 2025Article
- The interplay of tuberculosis and COVID-19: Insights into global health challenges.Journal of biosciences · 2025Review
- Multiscale computational model predicts how environmental changes and treatments affect microvascular remodeling in fibrotic disease.PNAS nexus · 2025Article
- Experimental dissection of tuberculosis protective immunity: a human perspective.Frontiers in cellular and infection microbiology · 2025Review
- Single nucleotide polymorphisms in IFN-gamma, TNF-alpha, IL-6, IL-10, and TGF-beta in pulmonary and extrapulmonary tuberculosis in the State of Ceará, northeastern Brazil.Memorias do Instituto Oswaldo Cruz · 2025Article
- Analysis of alpha-1-antitrypsin (AAT)-regulated, glucocorticoid receptor-dependent genes in macrophages reveals a novel host defense function of AAT.Physiological reports · 2024Article
- Multiscale computational model predicts how environmental changes and drug treatments affect microvascular remodeling in fibrotic disease.bioRxiv : the preprint server for biology · 2024Article
- Article
- Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.Frontiers in immunology · 2024Review
- The impact ofFrontiers in immunology · 2024Review
- In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models.PloS one · 2024Article
- A framework for multi-scale intervention modeling: virtual cohorts, virtual clinical trials, and model-to-model comparisons.Frontiers in systems biology · 2023Article
- Advances in the design of combination therapies for the treatment of tuberculosis.Expert opinion on drug discovery · 2023Review
- Novel Biomarker Panel of Let-7d-5p and MiR-140-5p Can Distinguish Latent Tuberculosis Infection from Active Tuberculosis Patients.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.